BioXcel Therapeutics
BTAI
49 hedge funds and large institutions have $1.89M invested in BioXcel Therapeutics in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 27 reducing their positions, and 29 closing their positions.
1.15% less ownership
Funds ownership: 1.63% → 0.48% (-1.2%)
34% less funds holding
Funds holding: 74 → 49 (-25)
35% less call options, than puts
Call options by funds: $22K | Put options by funds: $34K
74% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 27
85% less capital invested
Capital invested by funds: $12.5M → $1.89M (-$10.6M)
86% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$194K |
| 2 |
Renaissance Technologies
New York
|
+$109K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$43.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$26.3K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$25.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$3.82M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.82M |
| 3 |
Charles Schwab
San Francisco,
California
|
-$261K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$192K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$130K |
BTAI Hedge Fund Activity: Q3 2024 in Review
49 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q3 2024, worth a combined $1.89M — down 85% from $12.5M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of BTAI and 4 opened new positions — a net loss of 25 holders — while 27 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $194K. The largest seller was Armistice Capital, exiting entirely with an estimated $3.82M sold.
- 49 institutional investors held BioXcel Therapeutics (BTAI) as of Q3 2024, down from 74 in Q2 2024.
- Funds reported $1.89M of BioXcel Therapeutics stock for Q3 2024, down 85% quarter-over-quarter.
- 4 funds opened new BioXcel Therapeutics positions in Q3 2024 and 29 closed out, a net change of -25 holders.
- The largest BioXcel Therapeutics buyer in Q3 2024 was Vanguard Group, an estimated $194K added.
- The largest BioXcel Therapeutics seller in Q3 2024 was Armistice Capital, an estimated $3.82M sold.
Based on aggregated 13F filings for Q3 2024.